Literature DB >> 21330408

MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer.

Shahana Majid1, Sharanjot Saini, Altaf A Dar, Hiroshi Hirata, Varahram Shahryari, Yuichiro Tanaka, Soichiro Yamamura, Koji Ueno, Mohd Saif Zaman, Kamaldeep Singh, Inik Chang, Guoren Deng, Rajvir Dahiya.   

Abstract

The Src family of protein kinases (SFK) plays key roles in regulating fundamental cellular processes, including cell growth, differentiation, cell shape, migration, and survival, and specialized cell signals in various malignancies. The pleiotropic functions of SFKs in cancer make them promising targets for intervention. Here, we sought to investigate the role of microRNA-205 (miR-205) in inhibition of Src-mediated oncogenic pathways in renal cancer. We report that expression of miR-205 was significantly suppressed in renal cancer cell lines and tumors when compared with normal tissues and a nonmalignant cell line and is correlated inversely with the expression of SFKs. miR-205 significantly suppressed the luciferase activity of reporter plasmids containing the 3'-UTR (untranslated region) sequences complementary to either Src, Lyn, or Yes, which was abolished by mutations in these 3'-UTR regions. Overexpression of miR-205 in A498 cells reduced Src, Lyn, and Yes expression, both at mRNA and protein levels. Proliferation of renal cancer cells was suppressed by miR-205, mediated by the phospho-Src-regulated ERK1/2 pathway. Cell motility factor FAK (focal adhesion kinase) and STAT3 activation were also inhibited by miR-205. Transient and stable overexpression of miR-205 in A498 cells resulted in induction of G₀/G₁ cell-cycle arrest and apoptosis, as indicated by decreased levels of cyclin D1 and c-Myc, suppressed cell proliferation, colony formation, migration, and invasion in renal cancer cells. miR-205 also inhibited tumor cell growth in vivo. This is the first study showing that miR-205 inhibits proto-oncogenic SFKs, indicating a therapeutic potential of miR-205 in the treatment of renal cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21330408      PMCID: PMC3940352          DOI: 10.1158/0008-5472.CAN-10-3666

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  Focal adhesion kinase: the first ten years.

Authors:  J Thomas Parsons
Journal:  J Cell Sci       Date:  2003-04-15       Impact factor: 5.285

Review 2.  Cellular functions regulated by Src family kinases.

Authors:  S M Thomas; J S Brugge
Journal:  Annu Rev Cell Dev Biol       Date:  1997       Impact factor: 13.827

3.  Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis.

Authors:  C A Cartwright; A I Meisler; W Eckhart
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

4.  Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells.

Authors:  Gayathri R Devi; Jennifer R Oldenkamp; Carla A London; Patrick L Iversen
Journal:  Prostate       Date:  2002-11-01       Impact factor: 4.104

5.  Induction of cyclin D1 by simian virus 40 small tumor antigen.

Authors:  G Watanabe; A Howe; R J Lee; C Albanese; I W Shu; A N Karnezis; L Zon; J Kyriakis; K Rundell; R G Pestell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

6.  Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src.

Authors:  M V Barone; S A Courtneidge
Journal:  Nature       Date:  1995-11-30       Impact factor: 49.962

7.  Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions.

Authors:  C Albanese; J Johnson; G Watanabe; N Eklund; D Vu; A Arnold; R G Pestell
Journal:  J Biol Chem       Date:  1995-10-06       Impact factor: 5.157

8.  Reduced accumulation of specific microRNAs in colorectal neoplasia.

Authors:  Michael Z Michael; Susan M O' Connor; Nicholas G van Holst Pellekaan; Graeme P Young; Robert J James
Journal:  Mol Cancer Res       Date:  2003-10       Impact factor: 5.852

9.  Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness.

Authors:  Hiromichi Ito; James Gardner-Thorpe; Michael J Zinner; Stanley W Ashley; Edward E Whang
Journal:  Surgery       Date:  2003-08       Impact factor: 3.982

10.  Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice.

Authors:  P L Stein; H Vogel; P Soriano
Journal:  Genes Dev       Date:  1994-09-01       Impact factor: 11.361

View more
  73 in total

1.  Inducible deletion of epidermal Dicer and Drosha reveals multiple functions for miRNAs in postnatal skin.

Authors:  Monica Teta; Yeon Sook Choi; Tishina Okegbe; Gabrielle Wong; Oliver H Tam; Mark M W Chong; John T Seykora; Andras Nagy; Dan R Littman; Thomas Andl; Sarah E Millar
Journal:  Development       Date:  2012-04       Impact factor: 6.868

2.  MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Authors:  Lei Huo; Yan Wang; Yun Gong; Savitri Krishnamurthy; Jing Wang; Lixia Diao; Chang-Gong Liu; Xiuping Liu; Feng Lin; William F Symmans; Wei Wei; Xinna Zhang; Li Sun; Ricardo H Alvarez; Naoto T Ueno; Tamer M Fouad; Kenichi Harano; Bisrat G Debeb; Yun Wu; James Reuben; Massimo Cristofanilli; Zhuang Zuo
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

3.  MicroRNA-720 Regulates E-cadherin-αE-catenin Complex and Promotes Renal Cell Carcinoma.

Authors:  Nadeem S Bhat; Melissa Colden; Altaf A Dar; Sharanjot Saini; Prerna Arora; Varahram Shahryari; Soichiro Yamamura; Yuichiro Tanaka; Taku Kato; Shahana Majid; Rajvir Dahiya
Journal:  Mol Cancer Ther       Date:  2017-08-11       Impact factor: 6.261

4.  Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenesis.

Authors:  Tao Zhang; Junping Zhang; Ming Cui; Fabao Liu; Xiaona You; Yumei Du; Yuen Gao; Shuai Zhang; Zhanping Lu; Lihong Ye; Xiaodong Zhang
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

5.  miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways.

Authors:  Shahana Majid; Altaf A Dar; Sharanjot Saini; Varahram Shahryari; Sumit Arora; Mohd Saif Zaman; Inik Chang; Soichiro Yamamura; Yuichiro Tanaka; Takeshi Chiyomaru; Guoren Deng; Rajvir Dahiya
Journal:  Clin Cancer Res       Date:  2012-11-12       Impact factor: 12.531

6.  Elevated miR-182-5p Associates with Renal Cancer Cell Mitotic Arrest through Diminished MALAT-1 Expression.

Authors:  Priyanka Kulkarni; Pritha Dasgupta; Nadeem S Bhat; Varahram Shahryari; Marisa Shiina; Yutaka Hashimoto; Shahana Majid; Guoren Deng; Sharanjot Saini; Z Laura Tabatabai; Soichiro Yamamura; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Mol Cancer Res       Date:  2018-07-23       Impact factor: 5.852

7.  Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.

Authors:  Mingchao Wang; Yin Sun; Junjie Xu; Jieyang Lu; Kefeng Wang; Dong-Rong Yang; Guosheng Yang; Gonghui Li; Chawnshang Chang
Journal:  Int J Cancer       Date:  2018-04-02       Impact factor: 7.396

8.  MicroRNA-205 suppresses proliferation and promotes apoptosis in laryngeal squamous cell carcinoma.

Authors:  Linli Tian; Jiarui Zhang; Jingchun Ge; Hui Xiao; Jianguang Lu; Songbin Fu; Ming Liu; Yanan Sun
Journal:  Med Oncol       Date:  2013-12-03       Impact factor: 3.064

9.  miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer.

Authors:  Shahana Majid; Altaf A Dar; Sharanjot Saini; Sumit Arora; Varahram Shahryari; Mohd Saif Zaman; Inik Chang; Soichiro Yamamura; Yuichiro Tanaka; Guoren Deng; Rajvir Dahiya
Journal:  Cancer Res       Date:  2012-10-16       Impact factor: 12.701

10.  MicroRNA-205 directly regulates the tumor suppressor, interleukin-24, in human KB oral cancer cells.

Authors:  Jae-Sung Kim; Sun-Kyoung Yu; Myoung-Hwa Lee; Min-Gyeong Park; Euteum Park; Su-Gwan Kim; Sook-Young Lee; Chun Sung Kim; Heung-Joong Kim; Hong Sung Chun; Sang-Woo Chun; Do Kyung Kim
Journal:  Mol Cells       Date:  2012-12-03       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.